Objectives To report and describe the real-world use of ocrelizumab in women with multiple
sclerosis (MS) in Canada before and/or during pregnancy as well as their fetal outcomes …

Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …

Objective To assess the onset of ocrelizumab efficacy on brain MRI measures of disease
activity in the phase II study in relapsing-remitting multiple sclerosis (RRMS), and relapse …

Background Ocrelizumab is an approved MS treatment administered as two 300-mg
intravenous infusions 2 weeks apart (Dose 1), each lasting approximately 2.5 hours …

Progressive multiple sclerosis (PMS) is clinically distinct from relapsing–remitting MS
(RRMS). In PMS, clinical disability progression occurs independently of relapse activity …

Anti-CD 20 therapies have found significant uses in multiple sclerosis (MS). Based
singularly on the accumulated evidence with the use of rituximab (RTX; Rituxan, Genentech …

Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous
system. The latest development of B-cell depletion by anti-CD20 monoclonal antibodies has …

Background Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease
progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary …

Background: The efficacy and safety of ocrelizumab (OCR) in relapsing multiple sclerosis
(RMS) were demonstrated in the 96-week double-blind control period of OPERA I and …

Background B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …